Metabolic Health
GLP-1 and Inflammation
Semaglutide measurably lowers a key inflammation marker in trial data, independent of how much weight is lost. Here is w...
Most of the weight comes back. That is the honest answer, it is well documented, and anyone selling these drugs without saying it is misleading you.
Understanding why is what makes it manageable, because the reason is mechanical rather than a failure of character.
What the evidence shows
The STEP 1 trial, published in the New England Journal of Medicine, found semaglutide 2.4 mg produced an average 14.9 percent body weight reduction over 68 weeks.
Its extension study followed participants after treatment stopped. Within roughly a year of discontinuation, participants had regained around two thirds of the weight they had lost. Cardiometabolic improvements largely reverted alongside it.
A systematic review and meta-analysis of discontinuing GLP-1 receptor agonists examined this pattern across the drug class. The finding is consistent rather than specific to one drug.
This is not a fringe result or a marketing scare. It is the expected outcome.
Why it happens
Four mechanisms, none of which involve willpower.
Appetite signalling returns to baseline. The drug worked by amplifying a fullness signal. Remove it and the signal returns to whatever it was before. Hunger comes back, and it comes back to the level that produced the original weight.
Your body defends its previous weight. After weight loss, ghrelin rises and leptin falls, both pushing intake up. This response is well established after weight loss of any kind and can persist for years.
Resting energy expenditure falls. A lighter body burns fewer calories at rest, and the reduction is often greater than body size alone predicts. You need less food than before to maintain the same weight, while feeling hungrier.
Muscle loss compounds it. Any substantial calorie deficit costs some lean tissue. Less muscle means lower resting expenditure, which makes maintenance harder.
Put together, someone who stops treatment faces returning hunger, a lower calorie requirement and possibly less muscle than they started with. Regain under those conditions is a physiological outcome, not a moral one.
Why this is framed wrongly
The way people talk about this matters, because it drives bad decisions.
Nobody says a blood pressure medication "failed" because blood pressure rose after stopping it. Nobody describes stopping thyroid replacement and becoming hypothyroid again as a lack of discipline.
GLP-1 medication manages a condition while it is taken. Obesity is chronic and relapsing. Stopping treatment and seeing the condition return is how chronic disease treatment works.
The unhelpful conclusion is that these drugs "do not work." The accurate conclusion is that they work while taken, which is true of most treatments for chronic conditions.
What reduces the regain
Regain is not inevitable in full, and several things genuinely change the outcome.
Preserve muscle during loss. This is the highest-value action. Adequate protein at roughly 1.2 to 1.6 grams per kilogram daily, plus resistance training. Muscle protects resting energy expenditure, which is what makes maintenance possible.
Lose weight more slowly. Aggressive rapid loss costs more lean tissue than gradual loss. Faster is not better here.
Build the eating pattern during treatment, not after. The appetite suppression period is an opportunity to establish portion sizes, meal composition and habits while hunger is low. People who use that window keep more of the result. People who eat the same way and simply eat less have nothing to fall back on.
Do not stop abruptly if it can be avoided. Tapering under medical supervision is generally preferable to a sudden stop.
Keep weighing yourself. Early detection of a few kilograms is manageable. Discovering fifteen kilograms a year later is not.
Plan for maintenance before you finish. The end of a course is the highest-risk period and deserves as much thought as the start.
The maintenance question
For many people the honest answer is that treatment is long-term rather than a course with an end.
That is difficult in Pakistan specifically. Imported GLP-1 injections run Rs 20,000 to Rs 50,000 monthly with no registration, unreliable supply and no local price regulation. Indefinite treatment on that basis is not realistic for most households.
Which makes the planning question urgent rather than optional. If you know you cannot sustain treatment indefinitely, the habits and muscle you build during it are the only things that carry forward.
There is also emerging evidence on maintenance approaches. The ATTAIN-MAINTAIN trial tested whether people who lost weight on injectable Wegovy or Zepbound could switch to oral orforglipron and hold the loss, and it met its primary and all key secondary endpoints at 52 weeks. That suggests a future where a stronger agent does the initial work and a simpler one maintains. Neither drug is available in Pakistan.
What this means for choosing an approach
If regain after stopping is the central risk, then whether you can sustain something matters more than how strong it is.
A powerful treatment you stop after four months leaves you with returning hunger and a lower calorie requirement. A moderate approach you maintain, alongside habits and preserved muscle, produces a better long-term result.
That is the practical argument for the METASLIM™ program rather than a comparison of effect sizes. It is a physician-reviewed sublingual supplement working on the GLP-1 appetite pathway, with physician review before dispatch, and it does not produce STEP 1 results and should not be presented as though it does.
What it addresses is sustainability. A structured 8-week programme with dietary guidance is designed around building the pattern that survives it, rather than producing a number that reverses.
Our page on what the programme involves week by week covers that structure. Our guide to protein for weight loss covers the muscle preservation that matters most, and is weight loss medicine worth the cost works through the sustainability question.
The summary
Participants in the STEP 1 extension regained roughly two thirds of lost weight within a year of stopping, with cardiometabolic improvements largely reverting.
The causes are mechanical: appetite returns to baseline, the body defends its previous weight, resting expenditure falls, and lost muscle compounds it.
This is how treatment for a chronic condition behaves, not a failure of willpower.
Preserving muscle through adequate protein and resistance training is the single most effective countermeasure.
Habits built during treatment, while appetite is suppressed, are what carry forward afterwards.
Review the full program details if sustainability rather than peak effect is your priority.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.